Targeting EHMT2/ G9a for cancer therapy: progress and perspective.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173827
Abstract: Euchromatic histone lysine methyltransferase-2, also known as G9a, is a ubiquitously expressed SET domain-containing histone lysine methyltransferase linked with both facultative and constitutive heterochromatin formation and transcriptional repression. It is an essential developmental gene and… read more here.
Keywords: targeting ehmt2; ehmt2 g9a; cancer therapy; cancer ... See more keywords